MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
The transaction brings Lanthio Pharma's lead compound LP2, a novel lanthipeptide in development for diabetic nephropathy and fibrotic diseases to MorphoSys's growing proprietary portfolio.
|Searching for more deal information? Current Partnering offers the following options:
LP2, which will be re-named MOR107, has demonstrated potent angiotensin II type 2 (AT2) receptor-dependent activity in vivo, and is planned to enter clinical trials in 2016.
LP2 is the most advanced of four lanthipeptides in Lanthio Pharma's portfolio.
Prior to the acquisition, MorphoSys held 19.98% of Lanthio Pharma.
MorphoSys will pay EUR 20 million to acquire the outstanding share capital of Lanthio Pharma from the other investors, among them INKEF Capital, BioGeneration Ventures and Hanzepoort.
As part of its Innovation Capital initiative, MorphoSys had made its initial equity investment in November 2012 as part of Lanthio Pharma's Series A financing round.